Combining PI3K, CDK4/6 pathway inhibitors and immunotherapies in triple-negative breast cancer (TNBC): a novel therapy combination

PI3K、CDK4/6 通路抑制剂和免疫疗法相结合治疗三阴性乳腺癌 (TNBC)：一种新型疗法组合

• 批准号: nhmrc : 1123208
• 负责人: A/Pr Phillip Darcy
• 金额: $ 42.75万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/combining-pi3k-cdk46-therapy-combination/947101
• 关键词: Combining; PI3K; CDK4; pathway; inhibitors

Triple-negative breast cancer (TNBC) has the worst prognosis of all breast cancer subtypes, classically affecting young women and characterized by a lack of effective therapies. We show that blocking both PI3K and CDK4/6 pathways together effectively reduces TNBC growth in mice and can enhance anti-tumour immune responses. We aim to understand how these drugs work together and if adding immunotherapy can improve responses. Our project could provide a new treatment approach for TNBC patients.

三阴性乳腺癌(TNBC)是所有乳腺癌亚型中预后最差的，通常影响年轻女性，其特点是缺乏有效的治疗方法。我们发现，同时阻断PI3K和CDK4/6通路可以有效地减少小鼠TNBC的生长，并可以增强抗肿瘤免疫反应。我们的目标是了解这些药物是如何协同作用的，以及加入免疫疗法是否可以改善反应。我们的项目可以为TNBC患者提供一种新的治疗方法。